Beraksurf® is very first product of Tekzima in the market. Beraksurf® is a generic form of medicine exists in the market with the name of Survanta® (Beractant). However it could be a good substitute for other surfactants exist in the market.

Beraksurf® is a bovine pulmonary surfactant containing bovine lung extract which used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as SP-B and SP-C.

Beractant is a bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids, fatty acids, and bovine surfactant proteins). Pulmonary surfactant is a surface-active lipoprotein complex (phospholipo-protein) formed by type II alveolar cells.

Beractant contains two, hydrophobic low molecular weight surfactant-associated proteins commonly known as SP-B and SP-C.

The composition of the natural pulmonary surfactant may vary with such factors as species, age, lung compartment, disease states, diet, method of isolation, and so on. Surfactant isolated from lung of healthy mammals consists of about 90% lipids and 10% proteins. Ten percent to twenty percent of the lipids are neutral and the remaining 80% to 90% is PL. About 80% of PL is phosphatidylcholine (PC), about 50% to 60% of PC is DPPC, and about 10% of PL is PG. There are also small quantities of phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), and sphingomyelin (SM).

About a half of protein fraction of surfactant is composed of four surfactant-associated proteins: SP-A, SP-B, SP-C, and SP-D. Whereas SP-B and SP-C are extremely hydrophobic low-molecular-weight proteins, SP-A and SP-D are hydrophilic high-molecular-weight proteins from the protein family of collections. SP-A represents 4% of surfactant and SP-B and SP-C each make up less than 1%.

The proteins and lipids that make up the surfactant have both hydrophilic and hydrophobic reigns. By adsorbing to the air-water interface of alveoli, with hydrophilic head groups in the water and the hydrophobic tails facing towards the air, the main lipid component of surfactant, dipalmitoyl phosphatidylcholine (DPPC), reduces surface tension.

Endogenous pulmonary surfactant lowers surface tension on alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting pressures. Deficiency of surfactant causes respiratory distress syndrome (RDS) in premature infants. Beractant is similar to the natural fluid in the lungs that helps maintain effective breathing. As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome.

Beractant is given directly into the baby's lungs through a breathing tube that is also connected to a ventilator (a machine that moves air in and out of the lungs to help your baby breathe easier and get enough oxygen).

When Beractant is used as a replacement for deficient endogenous lung surfactant, it is effective in increasing pulmonary compliance by lowering surface tension on alveolar surfaces during respiration and stabilizing the alveoli against collapse at resting trans pulmonary pressures.

Surfactant Replacement Therapy for RDS ...

Contact us:





Address : No. 125, Km 22.5 of Tehran-Karaj special road. Tehran, Iran

Zipcode : 1399114913